Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Enfermedad de Alzheimer y Demencias

1569 ARTÍCULOS , VIENDO DEL 931 AL 945

Nanotechnology in Personalized Medicine: A Promising Tool for Alzheimer's Disease Treatment

De Matteis L, Martín-Rapún R, de la Fuente JM.

Curr Med Chem. 2018;25(35):4602-4615. doi: 10.2174/0929867324666171012112026.

Downregulated apoptosis and autophagy after anti-Aβ immunotherapy in Alzheimer's disease

Paquet C, Nicoll JA, Love S, Mouton-Liger F, Holmes C, Hugon J, Boche D.

Brain Pathol. 2018 Sep;28(5):603-610. doi: 10.1111/bpa.12567. Epub 2018 Feb 6.

Combining in vitro and in silico Approaches to Find New Candidate Drugs Targeting the Pathological Proteins Related to the Alzheimer's Disease

Li H, Wang X, Yu H, Zhu J, Jin H, Wang A, Yang Z.

Curr Neuropharmacol. 2018;16(6):758-768. doi: 10.2174/1570159X15666171030142108.

Cognitive Training in Patients with Alzheimer's Disease: Findings of a 12-month Randomized Controlled Trial

Trebbastoni A, Imbriano L, Podda L, Rendace L, Sacchetti ML, Campanelli A, D'Antonio F, de Lena C.

Curr Alzheimer Res. 2018 Mar 14;15(5):452-461. doi: 10.2174/1567205014666171113105044.

Potential of Low Dose Leuco-Methylthioninium Bis(Hydromethanesulphonate) (LMTM) Monotherapy for Treatment of Mild Alzheimer's Disease: Cohort Analysis as Modified Primary Outcome in a Phase III Clinical Trial

Wilcock GK, Gauthier S, Frisoni GB, Jia J, Hardlund JH, Moebius HJ, Bentham P, Kook KA, Schelter BO, Wischik DJ, Davis CS, Staff RT, Vuksanovic V, Ahearn T, Bracoud L, Shamsi K, Marek K, Seibyl J, Riedel G, Storey JMD, Harrington CR, Wischik CM.

J Alzheimers Dis. 2018;61(1):435-457. doi: 10.3233/JAD-170560.

Effects of Physical Exercise on Alzheimer's Disease Biomarkers: A Systematic Review of Intervention Studies

Frederiksen KS, Gjerum L, Waldemar G, Hasselbalch SG.

J Alzheimers Dis. 2018;61(1):359-372. doi: 10.3233/JAD-170567.

Longitudinal Neuroimaging Analysis in Mild-Moderate Alzheimer's Disease Patients Treated with Plasma Exchange with 5% Human Albumin

Cuberas-Borrós G, Roca I, Boada M, Tárraga L, Hernández I, Buendia M, Rubio L, Torres G, Bittini Á, Guzmán-de-Villoria JA, Pujadas F, Torres M, Núñez L, Castell J, Páez A.

J Alzheimers Dis. 2018;61(1):321-332. doi: 10.3233/JAD-170693.

Translational Research in Alzheimer's and Prion Diseases

Di Fede G, Giaccone G, Salmona M, Tagliavini F.

J Alzheimers Dis. 2018;62(3):1247-1259. doi: 10.3233/JAD-170770.

Phenolic Acids Exert Anticholinesterase and Cognition-Improving Effects

Szwajgier D, Baranowska-Wojcik E, Borowiec K.

Curr Alzheimer Res. 2018;15(6):531-543. doi: 10.2174/1567205014666171128102557.

Alzheimer: A Decade of Drug Design. Why Molecular Topology can be an Extra Edge?

Zanni R, Garcia-Domenech R, Galvez-Llompart M, Galvez J.

Curr Neuropharmacol. 2018;16(6):849-864. doi: 10.2174/1570159X15666171129102042.

Natural Product Formulations for the Prevention and Treatment of Alzheimer's disease: A Patent Review

Koynova R, Tenchov B.

Recent Pat Drug Deliv Formul. 2018;12(1):23-39. doi: 10.2174/1872211312666171207152326.

The Rationale and Design of the Reducing Pathology in Alzheimer's Disease through Angiotensin TaRgeting (RADAR) Trial

Kehoe PG, Blair PS, Howden B, Thomas DL, Malone IB, Horwood J, Clement C, Selman LE, Baber H, Lane A, Coulthard E, Passmore AP, Fox NC, Wilkinson IB, Ben-Shlomo Y.

J Alzheimers Dis. 2018;61(2):803-814. doi: 10.3233/JAD-170101.

While I Still Remember: 30 Years of Alzheimer's Disease Research

Shea TB.

J Alzheimers Dis. 2018;62(3):1049-1057. doi: 10.3233/JAD-170724.

Modeling Prion-Like Processing of Tau Protein in Alzheimer's Disease for Pharmaceutical Development

Wischik CM, Schelter BO, Wischik DJ, Storey JMD, Harrington CR.

J Alzheimers Dis. 2018;62(3):1287-1303. doi: 10.3233/JAD-170727.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias